RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Are you ahead, or behind on retirement? SmartAsset's free ...

This thesis makes the case for an investment in Recursion Pharmaceuticals operating as a TechBio which "industrializes" the process of drug discovery in contrast to a typical biotech. The difference ...

'Mad Money' host Jim Cramer weighs in on stocks including: Recursion Pharmaceuticals and NuScale Power. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more ...

Not only was there a "risk-off" mentality in the market today, but there were other fears surrounding biotech stocks in particular after a key FDA regulator resigned over the weekend. The FDA's chief ...

Recursion Pharmaceuticals is harnesing the power of artificial intelligence to rapidly develop new drugs. The drugmaker's former lead candidate failed to show evidence of efficacy in a phase 2 study ...